

Return potentials plus social value

Strategies in Focus: **Infrastructure and Private Equity**

Private equity is a broad asset class covering many sectors of the economy, investment styles and return profiles. From venture capital at one end of the risk-return spectrum to infrastructure at the other end, the asset class provides considerable opportunities for portfolio diversification and return enhancement. The two themes discussed below highlight this diversity.

Unfortunately, over the course of our lives, most of us will be touched by cancer either directly or through family and friends. Longer lifespans mean that cancer is now the leading cause of death. Fortunately, scientific advances have given rise to a new generation of oncology therapeutics with very positive outcomes. These advances arise from advances in the science dealing with genetics and from technology developments that have dramatically reduced the cost of genetic sequencing and molecular screening. Regulatory reform has also helped by accelerating drug approval processes.

Life science investments are currently at the forefront of venture capital

Much of the innovation in oncology therapeutics is originating from biotech start-up companies funded initially by venture capital. Ultimately, large pharmaceutical companies acquire and/or partner with these companies to bring the drugs to market. From an investor perspective, the promising trends in scientific knowledge and drug development coexist against a background of high and increasing expenditure on health.

Life science investments are at the forefront of venture capital at the moment accounting for 64% of venture capital IPOs in 2014. Oncology therapeutics is the hot spot in life sciences accounting for 30% of pharmaceutical biotech licensing activity in 2014. Investors are backing the scientific breakthroughs and facilitating the revolution in cancer treatment.

At the other end of the risk-return spectrum lies investing in infrastructure. It is no less important from a social perspective as it facilitates provision of the essential services that we all depend on. In fact, it is hard to find a government that is not supporting new and expanded investment in infrastructure at the moment.

Ultimately, infrastructure is an important contributor to productivity growth, and thus future economic growth rates, directly influencing citizens' standard of living.

Infrastructure has the lowest default rate and lowest loss given default within corporate debt

There are many investment strategies available for investing in infrastructure with the most recent innovation being institutional investment in infrastructure debt. This is consistent with the broader trend of institutional investment in private debt markets with infrastructure debt having the advantage of the lowest default rates and lowest loss given default of all classes of corporate debt.

Within this sector, additional opportunities for enhanced returns are available in the European markets where private investment in infrastructure is well developed and where, historically, the majority of infrastructure debt financing has been provided by private bank loans rather than public market issuance.

Taking advantage of the investment climate change and dislocated banking landscape

Changes in bank regulation have resulted in banks reducing lending to infrastructure companies at the same time as the demand for financing is increasing. Infrastructure debt funds are taking advantage of this change in the investment climate to facilitate institutional investment in the sector and fill the funding void created by the dislocation in the banking landscape.

The healthcare sector provides investment opportunities for both venture capital and infrastructure investors: from innovative therapies to state-of-the-art hospitals. Both types of investment have high social value and offer interesting risk-adjusted return potential.



Paul Moy is Head of Infrastructure and Private Equity and has responsibility for the global investment activities of this business. He was with UBS from 1999 to 2002 and rejoined in 2005. Paul has 30 years of industry experience.

This document does not replace portfolio and fund-specific materials. Commentary is at a macro or strategy level and is not with reference to any registered or other mutual fund.

EMEA: This document has been produced and issued by UBS Group AG and/or any of its affiliated companies (UBS). This document is for professional clients / qualified investors only. It is not to be distributed to or relied upon by retail clients under any circumstances. This document is a financial promotion and has been approved by UBS. It is intended solely for the attention of investment professionals, qualified institutional clients, sophisticated investors, professional investors and certain other qualified or accredited potential investors. This document is for marketing and information purposes only and no part of it may be used, copied, reproduced, distributed or otherwise passed on without the written permission of UBS. The information contained in this document is for discussion purposes only and does not contain all of the information that potential investors should consider before deciding whether or not to invest. This document: (i) is not a legal contract between you and UBS and (ii) does not constitute an offer to sell or a solicitation of an offer to buy, sell or render any investment, financial instrument or service. Offers or solicitations will be made, at UBS's discretion, to qualified investors by means of funds', services' or products' definitive offering materials, and nothing contained herein shall limit or amend the terms of any such offering. This document does not constitute investment advice or a personal recommendation. You should consult an appropriately qualified adviser as to the financial, legal and tax implications for you of your investment. Any statements made regarding performance, objectives, and risk/return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved. Any data/figures used in this document shall not be construed as indicative yields or returns. Investors should be aware that past performance data is not a guide to future performance. All investments involve risk including the risk of loss of some or all of your investment. An investment may not be suitable for all investors. The information used to produce this document (including the opinions contained herein) has been obtained from sources believed to be reliable. However, UBS does not accept responsibility for or warrant the accuracy, reasonableness and/or completeness of such information. All such information and opinions may no longer be current and are subject to change without notice. In particular, the investment strategies mentioned in this document may or may not be in existence yet. Accordingly the strategies outlined here may be varied before offering materials are finalized. A number of the comments in this document are based on current expectations and are considered "forward-looking" statements. Actual future results, however, may be different from expectations. This document does not constitute investment research and accordingly has not been prepared in accordance with any local requirements.

Source for all data and charts (if not indicated otherwise): UBS Asset Management, a business group within UBS.
© UBS 2016. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

UBS Deutschland AG
Asset Management
Bockenheimer Landstraße 2–4
60306 Frankfurt am Main
Tel. +49-69-1369-5300

www.ubs.com/deutschlandfonds